Breakthroughs in Alzheimer’s disease treatments
There was also a lot of interest in the lecanemab trial read-out.
Industry insiders said the trial would have a sizeable impact on the path forward for other biopharma companies developing treatments for Alzheimer’s disease.
Co-developed by Eisai and Biogen, the companies announced positive findings on the drug from the Clarity AD phase 3 trial on September 27, with the results suggesting lecanemab can slow cognitive and functional decline in a group of patients in the early stages of the disease.
Photo credit: GettyImages/Andrew Brookes